VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | Gemtuzumab ozogamicin in frontline AML therapy

Juliette Lambert, MD, Versailles Hospital, Le Chesnay, France, outlines the final efficacy and safety updates from the open-label, Phase III ALFA-0701 trial (NCT00927498) of gemtuzumab ozogamicin for de novo acute myeloid leukemia (AML). Additionally, Dr Lambert discusses the use of gemtuzumab ozogamicin in clinical practice. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter